{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:10:12Z","timestamp":1749183012917,"version":"3.41.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Acute migraine affects millions of people and is one of the most common primary care complaints in the United States. Available first-line abortive treatments are limited and vary in efficacy. Newer medications such as calcitonin gene-related peptide (CGRP) receptor antagonists may be a useful alternative. This article describes the use of ubrogepant, a new CGRP receptor antagonist, in a patient with contraindications to traditional medications used for acute migraine.<\/jats:p>","DOI":"10.1097\/01.jaa.0000931424.73007.a5","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T14:01:49Z","timestamp":1693922509000},"page":"25-28","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Treating acute migraine with ubrogepant"],"prefix":"10.1097","volume":"36","author":[{"given":"Erin S.","family":"Schoenfuss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"4","key":"R1-20250605","first-page":"243","article-title":"Acute migraine headache: treatment strategies","volume":"97","author":"Mayans","year":"2018","journal-title":"Am Fam Physician"},{"issue":"8","key":"R2-20250605","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/head.13588","article-title":"Unmet acute treatment needs from the 2017 migraine in America symptoms and treatment study","volume":"59","author":"Lipton","year":"2019","journal-title":"Headache"},{"issue":"3","key":"R3-20250605","first-page":"597","article-title":"Acute migraine treatment","volume":"27","author":"Ailani","year":"2021","journal-title":"Continuum"},{"issue":"suppl 4","key":"R4-20250605","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/head.12601","article-title":"Triptans in the acute treatment of migraine: a systematic review and network meta-analysis","volume":"55","author":"Cameron","year":"2015","journal-title":"Headache"},{"issue":"5","key":"R5-20250605","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1212\/WNL.0000000000009324","article-title":"Characterizing opioid use in a US population with migraine: results from the CaMEO study","volume":"95","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"107528","DOI":"10.1016\/j.pharmthera.2020.107528","article-title":"Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans","volume":"211","author":"De Vries","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"24","key":"R7-20250605","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"R8-20250605","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","article-title":"Acute migraine: can the new drugs clinically outpace","volume":"2","author":"Singh","year":"2020","journal-title":"SN Compr Clin Med"},{"issue":"1","key":"R10-20250605","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/head.13682","article-title":"Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial","volume":"60","author":"Ailani","year":"2020","journal-title":"Headache"},{"issue":"23","key":"R11-20250605","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"R13-20250605","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10268","key":"R14-20250605","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"R15-20250605","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/head.13444","article-title":"The emperor's new gepants: are the effects of the new oral CGRP antagonists clinically meaningful","volume":"59","author":"Tfelt-Hansen","year":"2019","journal-title":"Headache"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000931424.73007.a5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:04:38Z","timestamp":1749153878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000931424.73007.a5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000931424.73007.a5","relation":{},"ISSN":["1547-1896"],"issn-type":[{"type":"print","value":"1547-1896"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}